[go: up one dir, main page]

AU4388993A - Treatment of cellular hyperproliferation by inhibition of interleukin-1 - Google Patents

Treatment of cellular hyperproliferation by inhibition of interleukin-1

Info

Publication number
AU4388993A
AU4388993A AU43889/93A AU4388993A AU4388993A AU 4388993 A AU4388993 A AU 4388993A AU 43889/93 A AU43889/93 A AU 43889/93A AU 4388993 A AU4388993 A AU 4388993A AU 4388993 A AU4388993 A AU 4388993A
Authority
AU
Australia
Prior art keywords
oligomer
interleukin
cytokine
cells
target gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43889/93A
Other languages
English (en)
Inventor
Kevin D Cooper
Craig Hammerberg
Kameron W. Maxwell
Ben Y Tseng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
University of Michigan Ann Arbor
Original Assignee
Genta Inc
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc, University of Michigan Ann Arbor filed Critical Genta Inc
Publication of AU4388993A publication Critical patent/AU4388993A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/12Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/312Phosphonates
    • C12N2310/3125Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU43889/93A 1992-05-22 1993-05-21 Treatment of cellular hyperproliferation by inhibition of interleukin-1 Abandoned AU4388993A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88773492A 1992-05-22 1992-05-22
US887734 1992-05-22

Publications (1)

Publication Number Publication Date
AU4388993A true AU4388993A (en) 1993-12-30

Family

ID=25391751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43889/93A Abandoned AU4388993A (en) 1992-05-22 1993-05-21 Treatment of cellular hyperproliferation by inhibition of interleukin-1

Country Status (9)

Country Link
EP (1) EP0644765A4 (ja)
JP (1) JPH07508977A (ja)
KR (1) KR950701528A (ja)
AU (1) AU4388993A (ja)
CA (1) CA2136349A1 (ja)
IL (1) IL105741A0 (ja)
MX (1) MX9302951A (ja)
NZ (1) NZ253509A (ja)
WO (1) WO1993024134A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
JP4117904B2 (ja) 1996-03-01 2008-07-16 エーロスクレーン エッス.アー. C−c ckr−5,cc−ケモカインレセプタ、その誘導体及びこれらの利用
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0994743B1 (en) * 1997-07-10 2006-05-31 Therakos, Inc. Treatment of inflammatory disorders of the bowel or urinary bladder
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
GB0607189D0 (en) * 2006-04-10 2006-05-17 Polybiomed Ltd interleukin IL 1ra composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3056889A (en) * 1988-01-21 1989-08-11 Yale University Selective inhibition of gene expression by photoactivatable oligonucleotides
EP0527790A4 (en) * 1990-04-09 1993-09-15 The American National Red Cross Rejuvenation compositions and methods for their use
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
JPH06507911A (ja) * 1991-05-31 1994-09-08 ジンタ・インコーポレイテッド 中性オリゴマーを経皮投与するための組成物及び供給系
EP0600880B1 (en) * 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1- beta protease and interleukin 1-beta protease inhibitors

Also Published As

Publication number Publication date
WO1993024134A1 (en) 1993-12-09
KR950701528A (ko) 1995-04-28
EP0644765A4 (en) 1997-02-26
EP0644765A1 (en) 1995-03-29
MX9302951A (es) 1994-07-29
JPH07508977A (ja) 1995-10-05
NZ253509A (en) 1999-09-29
CA2136349A1 (en) 1993-12-09
IL105741A0 (en) 1993-09-22

Similar Documents

Publication Publication Date Title
EP0736093B1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
Tang et al. Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity
CN116801886B (zh) Lpa抑制剂及其用途
US6005094A (en) Oligonucleotide analogues having improved stability at acid pH
CA2152672A1 (en) Oligomers having improved stability at acid ph
EP0644765A1 (en) Treatment of cellular hyperproliferation by inhibition of interleukin-1
JPH10508760A (ja) raf遺伝子発現のアンチセンスオリゴヌクレオチド調節
JPH10510700A (ja) アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法
WO2000071703A2 (en) Inhibition of histone deacetylase
EP1141278B1 (en) Therapeutic pde4d phosphodiesterase inhibitors
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
JP2003505080A (ja) ヒトeg5の発現を阻害するためのオリゴヌクレオチド
EP0695354B1 (en) Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta1 (tgf-beta1)
JP2002523335A (ja) Vegf発現の抑制のためのアンチセンスオリゴヌクレオチド
CN114369130B (zh) 修饰的硫代寡核苷酸及其应用
EP0747386A2 (en) Method and antisense oligonucleotides to Interleukin-6 receptor mRNA for inhibiting cellular proliferation
US5716846A (en) Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA
KR102304280B1 (ko) 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
EP3500673B1 (en) Carboxylated 2'-amino-lna nucleotides and oligonucleotides comprising the same
EP0747480A1 (en) Oligonucleotides specific for cytokine signal transducer gp130 mRNA
CN119736294A (zh) 一种含碳环核苷的siRNA缀合物及其药物组合物和用途
US20040242519A1 (en) Antisense oligonucleotides for treatment of proliferating cells
Meng Synthesis and binding of oligonucleotides containing 2'-modified sulfide-or sulfone-linked dimers
MXPA01000910A (en) Antisense oligonucleotides for the inhibition of vegf expression
CZ2001419A3 (cs) Oligonukleotidy pro inhibici exprese VEGF, způsob jejich přípravy a jejich použití